88 related articles for article (PubMed ID: 23631847)
1. Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.
Bhatt VR; Ganti AK
Oral Oncol; 2013 Aug; 49(8):e25. PubMed ID: 23631847
[No Abstract] [Full Text] [Related]
2. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
3. Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?
Herchenhorn D; Ferreira CG
J Clin Oncol; 2011 Apr; 29(10):e283-4; author reply e285-7. PubMed ID: 21300921
[No Abstract] [Full Text] [Related]
4. Targeting the future in head and neck cancer.
Brizel DM
Lancet Oncol; 2009 Mar; 10(3):204-5. PubMed ID: 19261251
[No Abstract] [Full Text] [Related]
5. Combining targeted agents in lung cancer.
Belani CP; Adjei A
Clin Lung Cancer; 2004 Nov; 6(3):138. PubMed ID: 15555212
[No Abstract] [Full Text] [Related]
6. Head and neck cancer: second-line afatinib shows promise.
Killock D
Nat Rev Clin Oncol; 2015 Jul; 12(7):373. PubMed ID: 25940985
[No Abstract] [Full Text] [Related]
7. EGFR inhibition for recurrent or metastatic HNSCC.
Argiris A
Lancet Oncol; 2015 May; 16(5):488-9. PubMed ID: 25892143
[No Abstract] [Full Text] [Related]
8. [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
Dufresne A; Gainet M; Stein U; Guardiola E; Pivot X
Bull Cancer; 2003 Jan; 90(1):39-45. PubMed ID: 12609803
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab, temsirolimus plus or without cetuximab: combinational treatment against patients with advanced HNSCC.
Trafalis D; Alifieris C
J BUON; 2018; 23(6):1928-1929. PubMed ID: 30610825
[No Abstract] [Full Text] [Related]
10. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO
Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
[TBL] [Abstract][Full Text] [Related]
11. Integrating novel agents into the curative treatment of head and neck cancer.
Haddad R; Allen A; Wirth L; Tishler R; Posner M
Expert Rev Anticancer Ther; 2006 Feb; 6(2):157-9. PubMed ID: 16445367
[No Abstract] [Full Text] [Related]
12. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE
J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
[TBL] [Abstract][Full Text] [Related]
13. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Choe MS; Chen Z; Klass CM; Zhang X; Shin DM
Clin Cancer Res; 2007 May; 13(10):3015-23. PubMed ID: 17505004
[TBL] [Abstract][Full Text] [Related]
15. Failure of anti-EGFR therapy in p16-positive head and neck cancer.
Roesler R; Schwartsmann G
Lancet Oncol; 2013 Oct; 14(11):e436-e437. PubMed ID: 24079865
[No Abstract] [Full Text] [Related]
16. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
[TBL] [Abstract][Full Text] [Related]
17. Failure of anti-EGFR therapy in p16-positive head and neck cancer - authors' reply.
Vermorken JB; Bach BA
Lancet Oncol; 2013 Oct; 14(11):e437-e438. PubMed ID: 24079867
[No Abstract] [Full Text] [Related]
18. Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?
Trafalis DT; Alifieris C; Dalezis P; Geromichalos G; Sitaras NM
Anticancer Drugs; 2012 Sep; 23(8):874-82. PubMed ID: 22510794
[TBL] [Abstract][Full Text] [Related]
19. EGFR-directed treatments in SCCHN.
Vokes EE; Seiwert TY
Lancet Oncol; 2013 Jul; 14(8):672-3. PubMed ID: 23746667
[No Abstract] [Full Text] [Related]
20. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
